Products & Services · Total Revenues
Cobenfy — Total Revenues
Bristol-Myers Squibb Cobenfy — Total Revenues increased by 22.9% to $43.00M in Q3 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ3 2025
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful market penetration, strong physician adoption, and effective commercial execution for this specific therapy. A decrease may signal competitive pressure, access challenges, or slower-than-expected patient uptake.
Detailed definition
This metric represents the total net sales generated from the Cobenfy product line, a novel therapeutic treatment within...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or newly launched specialty pharmaceutical products at peer biopharmaceutical companies.
Metric ID:
bmy_segment_cobenfy_total_revenuesHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.00M | $27.00M | $35.00M | $43.00M |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | — | +170.0% | +29.6% | +22.9% |
Range$0.00 – $43.00M
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's cobenfy — total revenues?
- Bristol-Myers Squibb (BMY) reported cobenfy — total revenues of $43.00M in Q3 2025.
- What does cobenfy — total revenues mean?
- Total revenue generated from the sales of the Cobenfy therapeutic product.